Paul Tudor Jones's MDT Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 4,591 shares of Medtronic plc (MDT) worth $397,810, representing 0.00% of the portfolio. First purchased in 2014-Q4, this long-term strategic position has been held for 44 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in MDT, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2024, adding 233,878 shares. Largest reduction occurred in Q4 2023, reducing 315,803 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Medtronic plc (MDT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Medtronic plc (MDT) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +4,591 | New Buy | 4,591 | $86.65 |
| Q3 2025 | -6,177 | Sold Out | 0 | $0.00 |
| Q2 2025 | -11,860 | Reduce 65.75% | 6,177 | $87.17 |
| Q1 2025 | -91,888 | Reduce 83.59% | 18,037 | $89.86 |
| Q4 2024 | +109,925 | New Buy | 109,925 | $79.88 |
| Q3 2024 | -238,666 | Sold Out | 0 | $0.00 |
| Q2 2024 | +233,878 | Add 4884.67% | 238,666 | $78.71 |
| Q1 2024 | -30,045 | Reduce 86.25% | 4,788 | $87.15 |
| Q4 2023 | -315,803 | Reduce 90.07% | 34,833 | $82.38 |
| Q3 2023 | +49,172 | Add 16.31% | 350,636 | $78.36 |
| Q2 2023 | -58,240 | Reduce 16.19% | 301,464 | $88.10 |
| Q1 2023 | +113,862 | Add 46.32% | 359,704 | $0.08 |
| Q4 2022 | +45,139 | Add 22.49% | 245,842 | $0.08 |
| Q3 2022 | +151,332 | Add 306.52% | 200,703 | $80.75 |
| Q2 2022 | +49,371 | New Buy | 49,371 | $89.75 |
| Q1 2022 | -157,933 | Sold Out | 0 | $0.00 |
| Q4 2021 | +144,355 | Add 1063.15% | 157,933 | $103.45 |
| Q3 2021 | -9,537 | Reduce 41.26% | 13,578 | $125.35 |
| Q2 2021 | +5,309 | Add 29.82% | 23,115 | $124.12 |
| Q1 2021 | +17,806 | New Buy | 17,806 | $118.11 |
| Q4 2020 | -3,283 | Sold Out | 0 | $0.00 |
| Q3 2020 | +3,283 | New Buy | 3,283 | $103.87 |
| Q2 2020 | -6,956 | Sold Out | 0 | $0.00 |
| Q1 2020 | -6,274 | Reduce 47.42% | 6,956 | $90.14 |
| Q4 2019 | +13,230 | New Buy | 13,230 | $113.45 |
| Q2 2019 | -58,471 | Sold Out | 0 | $0.00 |
| Q1 2019 | +58,471 | New Buy | 58,471 | $91.09 |
| Q4 2018 | -11,351 | Sold Out | 0 | $0.00 |
| Q3 2018 | +7,844 | Add 223.67% | 11,351 | $98.41 |
| Q2 2018 | -18,783 | Reduce 84.27% | 3,507 | $85.54 |
| Q1 2018 | -21,041 | Reduce 48.56% | 22,290 | $80.22 |
| Q4 2017 | -15,508 | Reduce 26.36% | 43,331 | $80.75 |
| Q3 2017 | +39,254 | Add 200.43% | 58,839 | $77.77 |
| Q2 2017 | +7,794 | Add 66.10% | 19,585 | $88.74 |
| Q1 2017 | -31,007 | Reduce 72.45% | 11,791 | $80.57 |
| Q4 2016 | +38,698 | Add 943.85% | 42,798 | $71.24 |
| Q3 2016 | +100 | Add 2.50% | 4,100 | $86.34 |
| Q2 2016 | +4,000 | New Buy | 4,000 | $86.75 |
| Q1 2016 | -3,200 | Sold Out | 0 | $0.00 |
| Q4 2015 | -148,500 | Reduce 97.89% | 3,200 | $76.88 |
| Q3 2015 | +151,700 | New Buy | 151,700 | $66.94 |
| Q2 2015 | -11,800 | Sold Out | 0 | $0.00 |
| Q1 2015 | +8,000 | Add 210.53% | 11,800 | $77.97 |
| Q4 2014 | +3,800 | New Buy | 3,800 | $72.11 |
Paul Tudor Jones's Medtronic plc Investment FAQs
Paul Tudor Jones first purchased Medtronic plc (MDT) in Q4 2014, acquiring 3,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Medtronic plc (MDT) for 44 quarters since Q4 2014.
Paul Tudor Jones's largest addition to Medtronic plc (MDT) was in Q2 2024, adding 238,666 shares worth $18.79 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 4,591 shares of Medtronic plc (MDT), valued at approximately $397,810.
As of the Q1 2026 filing, Medtronic plc (MDT) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Medtronic plc (MDT) was 359,704 shares, as reported at the end of Q1 2023.